These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31329627)

  • 1. PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment.
    Bender H; Noyes N; Annis JL; Hitpas A; Mollnow L; Croak K; Kane S; Wagner K; Dow S; Zabel M
    PLoS One; 2019; 14(7):e0219995. PubMed ID: 31329627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes.
    Bender HR; Kane S; Zabel MD
    J Vis Exp; 2016 Jul; (113):. PubMed ID: 27501362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
    White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.
    Cortez LM; Campeau J; Norman G; Kalayil M; Van der Merwe J; McKenzie D; Sim VL
    J Virol; 2015 Aug; 89(15):7660-72. PubMed ID: 25972546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System.
    Zabel MD; Mollnow L; Bender H
    Methods Mol Biol; 2021; 2282():377-394. PubMed ID: 33928585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.
    Pulford B; Reim N; Bell A; Veatch J; Forster G; Bender H; Meyerett C; Hafeman S; Michel B; Johnson T; Wyckoff AC; Miele G; Julius C; Kranich J; Schenkel A; Dow S; Zabel MD
    PLoS One; 2010 Jun; 5(6):e11085. PubMed ID: 20559428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice.
    Ahn M; Bajsarowicz K; Oehler A; Lemus A; Bankiewicz K; DeArmond SJ
    PLoS One; 2014; 9(5):e98496. PubMed ID: 24866748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion protein-specific antibodies-development, modes of action and therapeutics application.
    Rovis TL; Legname G
    Viruses; 2014 Oct; 6(10):3719-37. PubMed ID: 25275428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
    Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
    J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?
    White MD; Mallucci GR
    CNS Neurol Disord Drug Targets; 2009 Nov; 8(5):342-52. PubMed ID: 19702576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for prion diseases: Insights from the use of RNA interference.
    White MD; Mallucci GR
    Prion; 2009; 3(3):121-8. PubMed ID: 19597349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.
    Minikel EV; Zhao HT; Le J; O'Moore J; Pitstick R; Graffam S; Carlson GA; Kavanaugh MP; Kriz J; Kim JB; Ma J; Wille H; Aiken J; McKenzie D; Doh-Ura K; Beck M; O'Keefe R; Stathopoulos J; Caron T; Schreiber SL; Carroll JB; Kordasiewicz HB; Cabin DE; Vallabh SM
    Nucleic Acids Res; 2020 Nov; 48(19):10615-10631. PubMed ID: 32776089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective gene therapy in a mouse model of prion diseases.
    Toupet K; Compan V; Crozet C; Mourton-Gilles C; Mestre-Francés N; Ibos F; Corbeau P; Verdier JM; Perrier V
    PLoS One; 2008 Jul; 3(7):e2773. PubMed ID: 18648643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.
    Lehmann S; Relano-Gines A; Resina S; Brillaud E; Casanova D; Vincent C; Hamela C; Poupeau S; Laffont M; Gabelle A; Delaby C; Belondrade M; Arnaud JD; Alvarez MT; Maurel JC; Maurel P; Crozet C
    PLoS One; 2014; 9(2):e88797. PubMed ID: 24551164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel regulators of PrP
    Colini Baldeschi A; Vanni S; Zattoni M; Legname G
    Expert Opin Ther Targets; 2020 Aug; 24(8):759-776. PubMed ID: 32631090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.
    Handisurya A; Gilch S; Winter D; Shafti-Keramat S; Maurer D; Schätzl HM; Kirnbauer R
    FEBS J; 2007 Apr; 274(7):1747-58. PubMed ID: 17313482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function.
    Leighton PL; Allison WT
    J Alzheimers Dis; 2016 Jul; 54(1):3-29. PubMed ID: 27392869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopeptide Delivery of siRNA to the Central Nervous System.
    Zabel MD; Mollnow L; Bender H
    Methods Mol Biol; 2019; 1943():389-403. PubMed ID: 30838631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific inhibition of pathological prion protein accumulation by small interfering RNAs.
    Daude N; Marella M; Chabry J
    J Cell Sci; 2003 Jul; 116(Pt 13):2775-9. PubMed ID: 12759373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.